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Bacillus Calmette-Gue´rin (BCG) is conventionally used as an adjuvant immunotherapy to reduce the recurrence of bladder cancer.
To address the issues of eﬃcacy and safety, an ethanol extract of Ganoderma lucidum (GLe) was evaluated for its interaction
with BCG. In a model of premalignant human uroepithelial cells (HUC-PC), GLe exerted immediate cytotoxic eﬀects while BCG
showed a delayed response, given that both were immunological active in inducing the secretion of interleukin (IL)-6, IL-8, and
monocyte chemotactic protein-1 (MCP-1). Synergistic cytotoxic eﬀects were observed when cells were either coincubated with
both drugs or firstly preincubated with GLe. Synergism between GLe and BCG was demonstrated to achieve a complete cytostasis
in 24 hours, and such eﬀects were progressed in the subsequent 5 days. However, the pretreatment of GLe resulted in suppression
of IL-6, IL-8, and MCP-1 secretions without aﬀecting the cytotoxicity. Given that numerous proinflammatory cytokines are
associated with the high side eﬀects toll of BCG, results herein suggested the potential implications of GL to supplement the
BCG immunotherapy in bladder cancer, for better eﬃcacy and reducing side eﬀects.
1. Introduction
Transitional cell carcinoma (TCC) of the urinary bladder is
known for its high recurrence rate up to 80% if patients are
treated by surgical ablation alone [1]. Despite the mecha-
nism of action is not fully understood, Bacillus Calmette-
Gue´rin(BCG) has been used for over 30 years as a prophy-
lactic agent for preventing the TCC recurrence. Intravesical
instillation of BCG following transurethral resection (TUR)
has shown an overall eﬀectiveness in diminishing 30–40% of
the recurrence and progression [2]. Such eﬀects were relied
on the mycobacterium nature of BCG, which was able to
trigger local nonspecific immune response through cytokines
secretion and recruitment of immune cells to the bladder
wall [3]. Several cytokines, some are sourced from urothelial
cells, were detected in patients’ voided urine upon BCG
instillation. In culture experiments, BCG was shown to be
active in stimulating tumor-necrosis-factor- (TNF-) related
apoptosis in accordance with the production of cytokines
including interleukin (IL)-1, IL-6, IL-8, and TNF-α, whereas
the activity was tumor grade dependent [4]. Besides, BCG
also leads to a high side eﬀect toll of 90% from local
cystitis and haematuria, allergic reactions to severe systemic
infection [5]. Controversially, the immunological activities
induced by BCG, especially some of the cytokines, were
suggested as the side eﬀects cause [6, 7]. Therefore, a new
chemopreventive regimen with better eﬃcacy and lesser side
eﬀects is demanded.
The recurrence of TCC was associated with the presence
of papillary multifocality. This is explained by the “field
cancerization hypothesis” and the “clonal seeding theory”
that residual adverse cells at premalignant stage could not
be completely removed by surgery, and thus they are readily
being transformed by any stimulation [1]. In this relation,
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for evaluating potential bladder prophylactic agents, we
postulated the importance of utilizing a human uroepithelial
(HUC-PC) cell line, which carries the premalignant features
of being sensitive to bladder carcinogens for undergoing
tumorigenic transformation [8]. Ganoderma lucidum, an
ancient medicinal mushroom belonging to the family of
Ganodermataceae of Aphyllophorales, has been widely used
for promotion of health and longevity. Its popularity and
perceived health benefits have also prompted the usage
by cancer patients. With polysaccharides and triterpenes
as principle bioactive constituents, a range of scientific
evidence from in vitro to animals and humans in vivo has
been discovered for supporting the antitumorigenicity of G.
lucidum in cancer of diﬀerent origins [9]. In the past years,
some works have been done to explore the chemopreventive
properties of this mushroom on TCC. Antiproliferation was
demonstrated on TCC cells with diﬀerent degrees of malig-
nancy, from premalignant to high-grade invasive [10]. In the
premalignant HUC-PC cells, growth inhibition via G2/M
phase cell cycle arrest and apoptosis was shown by ethanol
extract of G. lucidum (GLe), in addition to the suppression
of carcinogen 4-aminobiphenyl-mediated cell migration and
telomerase activity [10, 11]. More recently, GLe was found
to be immunologically active to induce secretion of an array
of cytokines secretion and neutrophilic migration, in the
culture of HUC-PC cells [12]. Such properties generate
the next question to ask whether GLe could be synergistic
with BCG in elimination of adverse cells of TCC. By using
the HUC-PC cell model, a pilot study was conducted and
indicated that BCG was noncytotoxic in 24 hours after
incubation but stimulated a dose-dependent IL-6 production
via nuclear factor-kappa B (NF-κB) pathways. In the present
study, interaction between GLe and BCG was evaluated
using two treatment approaches: combination therapy and
a pretreatment of GLe followed by BCG treatment. Cell
viability and expression of cytokines (T-helper (Th)1, Th2
cytokines and chemokines) in response to the treatments
were investigated as outcome measures. Furthermore, the
cytotoxicities induced by test agents were assessed in a
prolonged period, in order to confirm the persistence or
delay of response.
2. Materials andMethods
2.1. G. lucidum Extract and Chemicals. A proprietary extract
consisting of G. lucidum fruiting bodies and cracked spores,
branded ReishiMax GLP, was purchased from Pharmanex
Inc. (Hong Kong). The active ingredients of the product
were standardized to 13.5% polysaccharides (β-1,3-glucans)
and 6% triterpene (ganoderic acids and others), which is
the highest extractable levels, whereas the remaining 80%
consisted of nucleosides, fatty acids, and amino acid accord-
ing to the manufacturer’s technical bulletin. The powdered
G. lucidum from capsules was re-extracted as previously
described [11]. Briefly, capsule contents were dissolved
in 95% HPLC grade ethanol for 30 minutes, and the
supernatant was further extracted by successive sonication
using absolute ethanol. The reextracts were filtered (through
0.45 μm polypropylene filter) and dried under reduced
pressure to yield a water-insoluble extract (GLe) as brown-
colored powder. For experiments, the GLe was dissolved
in absolute ethanol (with final solvent concentration below
0.01% vol/vol), and then immediately diluted to 200 μg/mL
GLe assay media stock with complete media before adding
into cultures. Immucyst BCG was sourced from Aventis
(Toronto, Canada). The whole vial of attenuated BCG (81mg
dry weight containing 5% monosodium glutamine) was
reconstituted with 3mL of the accompanying diluents to
make a stock solution containing a minimal 6.6× 108 colony
forming units (CFU). The stock solution was further diluted
with complete medium into the working concentrations
for culture. The Limulus Amebocyte Lysate (LAL) endpoint
chromogenic kit assay (CAPE CO, E. Falmouth, MA, USA)
was performed to detect lipopolysaccharides (LPS) contam-
ination in the GLe and BCG. In this assay, Glucashield
buﬀer (CAPE COD) was used to reconstitute pyrochrome
to inhibit possible (1, 3)-β-D-glucan present in samples, and
thus avoiding potential interference. Aseptic techniques were
strictly applied throughout the procedures.
2.2. Cell Culture and Treatment. The HUC-PC cell line
(provided by Dr. Rao from the University of California,
Los Angeles, USA) was cultured in F12-Ham enhanced
Dulbecco’s Modified EaGLe’s Medium (Sigma, St. Louis,
USA) with 1% penicillin (10,000 μg/mL) and streptomycin
(10mg/mL) and 10% fetal bovine serum (Gibco Brl Island,
New York, USA). All cultures were maintained at 37◦C
in a water-saturated atmosphere containing 5% CO2. The
eﬀects of BCG were tested with or without GLe by using 4
diﬀerent treatment schedules (2 of them were for synergism)
illustrated in Figure 1. Logarithmically growing cells were
plated in 6-well culture plates at 1.25 × 105 cells per well for
treatment 1–3 and 2.5×105 cells per well for treatment 4. The
diﬀerent cell seeding density in treatment 4 was set to obtain
the closest baseline cell numbers as other treatment schedules
when corresponding treatment initiated. Treatment 1 and 2
were used to test BCG (at 0, 1.2×107, 2.4×107, and 4.8×107
CFU) andGLe (0, 40, 80, 100 μg/mL), respectively. Treatment
3 was the combination test for BCG (at fixed concentration
of 1.2 × 107 CFU) with diﬀerent concentrations of GLe
listed above. Whilst treatment 4 was the GLe-pretreatment
protocol that a 24-hour BCG treatment was given following
the 24-hour GLe pretreatment. For all treatment schedules,
culture media and cells were harvested when the correspond-
ing treatment was completed, and used for measuring the
cytokine levels and viable cell count (day 1), respectively. In
parallel experiments, cultures were maintained after removal
of assay media and pure complete media (in the absence
BCG or GLe) was refreshed every 2 days to ensure nutrient
supply. On day 6 (5 days after retraction of treatment), cells
were harvested for viable cell count. Cytokine levels were
not determined on day 6 because preliminary data indicated
that vast cytotoxicities have appeared in many of the treated
cultures that number of viable cells was insuﬃcient for
cytokines production. Cells treated with solvent media, that
is, 0.1% v/v ethanol for GLe and 33% v/v diluents for BCG
were used as control experiments.
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Figure 1: The treatment schedules for experiments, illustrating 4 treatments (T1–T4) were tested. A 24-hour incubation was allowed for
stabilizing the culture environment after seeding the cells. The initial cell seeding numbers of T1–T3 were halves of T4, because cell cultures
for T1–T3 weremaintained for an additional 24 hours in complete media, in order to align initial cell numbers for all treatment groups before
the first day sampling (Day 0 as baseline), that is, approximately 2.5× 105 cells since doubling time for the HUC-PC cells was 24 hours. For
T4, a range of GLe concentrations was administrated before the baseline, and this complete medium in the absence of GLe (0 μg/mL) was
used as the baseline for this treatment group. Subsequent samples were collected on Day 1 (Day 3 after initial cell seeding) and Day 6 (Day 8
after initial cell seeding) following diﬀerent treatments.
2.3. Cytotoxicity Assay. Cell viability was assessed by the
automated Beckman Coulter Vi-CELL XR cell viability
analyzer with its reagent pack (Miami, FL, USA). All cell
counting results were verified between the manual and
automated methods and expressed as the viable cell numbers
for interpretation.
2.4. FlowCytomix for Cytokines Measurement. The Flow-
Cytomix (Bender MedSystems, Austria) human Th1/Th2
11plex and human chemokine 6plex kits were used for
cytokines measurement. In total, 15 cytokines: interferon-
(IFN)-γ, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70,
tumor necrosis factor (TNF)-, TNF-β, monocyte chemotac-
tic protein-1 (MCP-1), granulocyte colony stimulating factor
(G-CSF), monokine induced by interferon gamma (MIG),
macrophage inflammatory protein(MIP)-1α, and MIP-1β
were measured, whereas IL-8 was overlapped in both kits.
The Cytomics FC500 Flow cytometer (Beckman Coulter,
Miami) equipped with CXP software version 2.2 was used.
The forward scatter measurements were collected at 1–8
degrees. Standard mixture was prepared for each kit by
mixing the standard of each analyte. The setup beads and
standard mixture with highest phycoerythrin (PE) signal
(FL-2 585/42 BP for detection) were used to set up the
flow cytometry. Dilutions of each standard mixture (total
7 concentrations) were used to create the standard curve.
And concentrations of each cytokine in the harvest media
were analyzed and read against the corresponding standard
curve using the FlowCytomix Pro software (Version 2.2,
Bender Medsystem, Austria). Coeﬃcients of variation <15%
and absence of mavericks were achieved for reliable standard
curves.
2.5. Statistical Analysis. All assays were performed in tripli-
cate for reproducibility. Descriptive statistics with mean ±
standard deviation were used to summarize the results.
Diﬀerences between means were determined using the one-
way analysis of variance (ANOVA) followed by Dunnett’s
test (GraphPad Prism version 3.0 for Windows, San Diego,
Ca, USA), whereas statistical significance was sought at two-
tailed P-value of 0.05.
3. Results
3.1. Diﬀerentiated Properties of BCG and GLe on HUC-
PC Cells. Immediately after the 24-hour incubation, no
cytotoxicity was demonstrated by BCG, except at 1.2 ×
107 CFU, about 15% of viable cell number was reduced
(statistically nonsignificant). Nonetheless, a dose-dependent
growth inhibition was observed 5 days after the BCG retrac-
tion (Figure 2(a)). In contrast, remarkable dose-dependent
growth suppression was observed immediately after the 24-
hour incubation with GLe, whereas the cytostatic eﬀects were
further progressed to become more significant in the next
5 days after GLe withdrawal (Figure 2(b)). Consistent with
previous findings [11, 13], GLe at 80 μg/mL was shown to be
growth suppressing that was able to maintain the cell culture
at initial seeding cell density for at least 5 days following GLe
treatment (as shown in Figure 2(b)) but became cytotoxic
to eliminate the adverse cells when concentration reached
100 μg/mL or above.
Cytokine secretion following diﬀerent treatment sched-
ules were summarized in Table 1. Amongst the 15 cytokines
tested, only IL-6, IL-8, andMCP-1 were detectable in the cul-
tures of HUC-PC cells without treatment. BCG (treatment 1)
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Figure 2: Showing the immediate and progressive cytotoxic
eﬀects exhibited by (a) BCG on day 1 (F = 4.908; statistically
nonsignificant) and day 6 (F = 51.30; ∗∗∗P < 0.001), and (b) GLe
on day 1 (F = 18.69; ∗∗∗P < 0.001) and day 6 (F = 118.5; ∗∗∗P <
0.001). Results of BCG and GLe were statistically compared with the
solvent media control according to the corresponding schedule (i.e.,
day 1 versus Day 1 and Day 6 versus Day 6), at 0 CFU containing
BCG diluents (33% v/v) and at 0 μg/mL containing ethanol (0.1%;
v/v), respectively. All experiments were performed in triplicate for
reproducibility. F value of each treatment group was determined by
one-way ANOVA, and Dunnett’s posttest was followed to determine
P values.
andGLe (treatment 2) exhibited similar activities in inducing
IL-6 and IL-8 production (P < 0.001), reducingMCP-1 levels
(P < 0.001 for all GLe concentrations but P < 0.001 for BCG
at 1.2× 107 CFU only). The increase or decrease of cytokines
demonstrated by GLe was in clear dose-dependent manner,
whereas GLe has also stimulated a trace amount of IL-2
production but statistically nonsignificant. On the contrary,
the BCG-mediated cytokines were not dose dependent.
3.2. Synergistic Cytotoxicity between GLe and BCG. The
interaction between GLe and BCG on HUC-PC cells was
evaluated by another two treatment schedules (treatment 3
and 4 illustrated in Figure 1). Irrespective of combination
treatment with GLe (treatment 3) or pretreatment of GLe
(treatment 4), the growth inhibitory activities induced by
1.2 × 107 CFU of BCG were significantly enhanced. Cell
growth was completely halted (maintaining the initial cell
density) and was observed in the 24-hour combination
treatment of 80 μg/mL GLe with 1.2 × 107 CFU BCG
(Figure 3(a)). In the following 5 days when the treatment was
removed, viable cell numbers were reduced below the initial
cell density by all test concentrations, of which 6%, 65%,
and 80% of the HUC-PC cells were eliminated by combining
1.2 × 107 CFU BCG with 40, 80, and 100 μg/mL of GLe,
respectively. On the other hand, cytotoxic activities of BCG
were remarkably promoted and fastened by the pretreatment
with GLe (treatment 4; Figure 3(b)). About 25% and 40% of
the initial cell densities were eliminated by the pretreatment
with 80 and 100 μg/mL of GLe, respectively, immediately
after complete cessation of BCG. Such cytotoxic eﬀects were
further progressed in the next 5 days, with about 60% cell
reduction by 40 or 80 μg/mL GLe and 73% cell elimination
by 100 μg/mL GLe. To confirm the relationship between GLe
and BCG, combination index (CI) values were determined
for treatment groups 3 and 4, where CI < 1 indicates
synergism, CI > 1 indicates antagonism, and CI = 1 indicates
additive eﬀect. Our results (Figure 4(c)) clearly showed that
HUC-PC cells treated with BCG showed synergistic loss
of cell viability when combined with GLe (CI = 0.91) or
pretreated with GLe (CI = 0.81).
3.3. Regulatory Activities of GLe on BCG-Mediated Cytokines.
The coincubation of BCG and GLe (treatment 3) has
promoted the secretion of IL6 dose-dependently and
has diminished the production of IL-8 (statistically
nonsignificant) and MCP-1 (P < 0.001) (Table 1).
Oppositely, all BCG-mediated cytokines (IL-6, IL-8,
and MCP-1) were dramatically (P < 0.001) suppressed by
the 24-hour GLe pretreatment (Table 1). In particularly,
MCP-1 level of HUC-PC cells in treatment 4 was dropped
to nondetectable level when pretreated with 100 μg/mL of
GLe. However, IL-2 was not detectable in all cultures treated
under treatment 3 or 4 schedules.
4. Discussion
Current in vitro study reports encouraging findings that
ethanol extract of Ganoderma lucidum exhibited synergistic
cytotoxic eﬀects with BCG on the adverse uroepithelial cells
at premalignant stage, in addition to its regulatory eﬀects on
proinflammatory cytokines including IL-6, IL-8, and MCP-
1. Further to our previously reported growth inhibitory
properties of GLe, this is the first time to demonstrate that
cytotoxicity of GLe or BCG was progressed continuously
even after the treatment withdrawal. However, the BCG
cytotoxicity exhibited on the HUC-PC cells was shown to be
delayed after the BCG cessation.
Previous studies on BCG cytotoxicity were mainly
focused on high-grade tumor cells [15], which may not be
able to reflect the actual clinical implications in removing the
residual cells from the bladder wall. Apoptosis was induced
on bladder cancer cell lines of grade 3 and 4 stages by the wall
preparation of mycobacterium species [16]. In low-grade
bladder tumor cell lines, cell cycle arrests were observed after
exposing to BCG, but no DNA degradation was shown, and
therefore, apoptotic eﬀects could not be confirmed [17].
Besides, the authors postulated that those residual adverse
cells following surgical ablation are premalignant rather than
Evidence-Based Complementary and Alternative Medicine 5
Table 1: Yuen et al.
Treatment schedule
Cytokine level (Mean ± SD); n = 3
IL-2 (pg/mL) IL-6 (pg/mL) IL-8 (pg/mL) MCP-1 (pg/mL)
Treatment 1 (24 hours)
BCG alone 0 CFU† N.D. 76± 21 744± 193 1812± 124
1.2× 107 CFU N.D. 380± 25∗∗∗ 1629± 416∗∗∗ 1850± 258
2.4× 107 CFU N.D. 492± 29∗∗∗ 1580± 503∗∗∗ 1661± 278
4.8× 107 CFU N.D. 498± 35∗∗∗ 1651± 708∗∗∗ 1490± 170∗∗∗
(F = 1093) (F = 20.82) (F = 5.044)
Treatment 2 (24 hours)
GLe alone 0 μg/mL† 6± 11 57± 24 645± 102 1765± 115
40 μg/mL 7± 13 331± 37∗∗∗ 1581± 367∗∗∗ 1254± 101∗∗∗
80 μg/mL 10± 19 822± 35∗∗∗ 2430± 397∗∗∗ 740± 71∗∗∗
100 μg/mL 22± 29 1343± 130∗∗∗ 3091± 672∗∗∗ 671± 62∗∗∗
(F = 1.238) (F = 541.6) (F = 105.2) (F = 280.6)
Treatment 3 (24 hours)
BCG + GLe 0 μg/mL† N.D. 413± 202 1835± 808 1789± 308
1.2× 107 CFU 40 μg/mL N.D. 752± 39∗ 1733± 469 520± 137∗∗∗
80 μg/mL N.D. 754± 83∗∗∗ 1504± 328 818± 169∗∗∗
100 μg/mL N.D. 891± 40∗∗∗ 1436± 338 542± 101∗∗∗
(F = 11.12) (F = 1.628) (F = 42.89)
Treatment 4 (48 hours)
24-hr GLe → 24-hr BCG 0 μg/mL† N.D. 640± 44 2256± 830 3471± 338
1.2× 107 CFU 40 μg/mL N.D. 270± 27∗∗∗ 874± 68∗∗∗ 962± 107∗∗∗
80 μg/mL N.D. 164± 31∗∗∗ 524± 243∗∗∗ 89± 103∗∗∗
100 μg/mL N.D. 161± 20∗∗∗ 634± 206∗∗∗ N.D.∗∗∗
(F = 827.2) (F = 43.45) (F = 269.3)
The secretion of cytokines detectable in the conditioned media collected from the cells treated with diﬀerent treatment schedules (N.D.: non-detectable;
∗P < 0.05; ∗∗∗P < 0.001). Statistical significances of parameters in each treatment schedule group were compared with corresponding control†. Controls
for treatment 1 and 2 were not identical, because the 0 CFU BCG in treatment 1 contains 33% (v/v) BCG diluents, whereas the 0 μg/mL GLe in treatment
2 contains 0.1% (v/v) ethanol. Additionally, the diluting eﬀect of BCG diluents in the complete media was suspected to be the cause of non-detectable level
of IL-2 in treatment 1, as compared with the trace level produced in the GLe control in treatment 2. However, the secretion of other cytokines (IL-6, IL-8
and MCP-1 were not in trace amounts) was seemed to be not being aﬀected by such dilution. F value of each treatment group was determined by one-way
ANOVA, and Dunnett’s post test was followed to determine P values.
malignant, since patients are apparently cured with complete
tumor foci clearance. Herein, BCG has only demonstrated
at the lowest tested concentration at 1.2 × 107 CFU a small
reduction (about 15%) in viable cell number. Such cytotoxic
eﬀects were not observed at higher concentrations tested,
in which the mechanism is uncertain. Action of BCG is
believed to be relied on the inflammatory response upon
urothelial internalization [18]. Subsequently, the expression
of TNF-related apoptosis-inducing ligand (TRAIL/Apo2L)
and Fas/CD95 ligand (FasL) was stimulated on infiltrated
immune cells and Fas expression on tumor cells, resulting
in tumor necrosis factor-alpha (TNF-α-) induced apoptosis
[4, 19]. It was also supported by the findings that voided
urine samples from TCC patients receiving BCG therapy
were cytotoxic to RT-4 bladder cancer cells [4]. High levels
of functional soluble forms of TRAIL were detected in such
specimens [20]. In the present study, neither TNF-α nor IFN-
γ was stimulated by the BCG treatment at the measured
time point. However, FlowCytomix results revealed that IL-
6 and IL-8 secretions were induced in the culture media
of BCG-treated HUC-PC cells. IL-6 has evidenced for
the ability in inducing interferon-gamma (IFN-γ), which
is believed as a late responsive T-helper type 1 cytokine
to stimulate the TRAIL expression, thus responsible for
successful BCG prophylaxis [21, 22]. Thus, current findings
speculate the delay of BCG cytotoxicity was due to the
process of BCG internalization and subsequent immune
response, which requiring further elucidation.
On the other hand, activities of GLe have shown to be a
fast action that early apoptotic events with positive annexin-
V uptake were initiated at 3 hours during the 24-hour
incubation course [11]. Consistent with the reported G2M
phase cell arrest in HUC-PC and other TCC cell lines [10],
results herein have further demonstrated the progressing
cytotoxicity and driven the complete adverse cell clearance
several days after treatment retraction, especially at dose
80 μg/mL or above. However, before the GLe cytotoxicity
can be translated into clinical applications, the specificity
of such cytotoxicity to carcinoma or adverse cells must be
defined. In preliminary studies, GLe has shown to exert mild
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cytotoxicity to normal uroepithelial (HUC-1) cells, but in
a lesser extent than in the HUC-PC cells (data not shown),
which suggests the selectivity on premalignant instead of
normal urothelium. This is also consistent with the selective
cytotoxic eﬀects of G. lucidum on cancer cell lines versus
normal cells in origins instead of urinary bladder [23].
Besides the antitumor activities, the administration of G.
ludicum has increased the lifespan in tumor-bearing mice of
mammary cancer and did not display any toxicity [24]. In
human in vivo, G. lucidum did not cause toxic eﬀects to harm
the liver and kidneys of patients with breast cancer receiving
conventional endocrine therapy, whereas the well-being and
cancer-related fatigue were also improved [25].
Similar to the BCG activities, GLe was also shown to
stimulate IL-6 and IL-8 in the HUC-PC cells. Induction
of IL-6 secretion by other G. lucidum fractions has been
reported from various cell types including human T cells
and mouse splenocytes [26, 27]. The GLe-mediated IL-8
secretion was also correlated with neutrophilic chemotaxis
attraction thatmay facilitate the apoptotic cell clearance [12].
Given that nuclear factor-κB (NF-κB) and activating protein-
1 (AP-1) are the main signaling pathways responsible for
cytokines induction, the expression of IL-6 mRNA in the
Hu35E6E7 HUC cells was found to be exclusively triggered
by BCG through the Toll-Like Receptor (TLR) signaling
[28]. Whilst p50/65 NF-κB activity was enhanced by GLe
concurrent with the cytokine elevation in the HUC-PC cells
[12]. Therefore, the next question we asked was whether GLe
would interact with BCG to favor TCC prophylaxis and how.
Based on the hypothesis that BCG induces interferon-
(IFN-) medicated cytotoxicity for the residual cell clearance,
a 50–60% initial response rate was evidenced in resistant and
relapsing patients after receiving the intravesical instillation
of IFN-α2B and reduced dose of BCG [29]. Antitumor activ-
ities on bladder cancer cells were demonstrated by the combi-
nation treatment of Maitake mushroom with IFN-α [30]. In
the present study, the cytotoxic eﬀects exhibited by GLe and
BCG were shown to be additive when cells were coincubated
with both drugs or preincubated with GLe first. Despite the
fact that both GLe and BCG are immunologically active, in
the HUC-PC cultures, pretreatment with GLe was shown to
be suppressive on all BCG-mediated cytokines. However, IL-
6 induced by BCG was further stimulated when coincubated
with GLe, while IL-8 secretion was inhibited. Such results
implied that the inactivation of cytokine induction did not
compromise the overall cytotoxicity, suggesting that the
BCG and GLe synergism was cytokine-independent. On the
contrary, the reduction of cytokine could be explained by
the dramatic cytotoxic eﬀects that essential metabolisms are
commonly ceased during cell termination [31]. This could
be explained by the early priming of HUC-PC cells by GLe
to undergo progressive apoptosis before BCG was added
[11]. Coherently, the antineoplastic properties of BCG on
TCC cell lines [32] and mice in vivo [33] were enhanced
by a vascular endothelial growth factor (VEGF)—Sunitinib
through apoptotic pathways. Besides the therapeutic eﬃcacy,
bacterial infection and subsequent inflammatory response
following intravesical BCG instillation are also associated
with the high side eﬀect tolls [7]. Despite such adverse eﬀects
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Figure 3: Showing the immediate and progressive cytotoxic eﬀects
exhibited by (a) coincubation of GLe with BCG on day 1 (F =
14.14; ∗∗∗P < 0.01) and day 6 (F = 217.6; ∗∗∗P < 0.001), and
(b) pretreatment of GLe followed by BCG on day 1 (F = 169.8;
∗∗∗P < 0.001) and day 6 (F = 30.52; ∗∗∗P < 0.01). For all test
conditions, BCG concentration was fixed at 1.2 × 107 CFU for
testing diﬀerent concentrations of GLe. Results were statistically
compared with control at 0GLe concentration but treated with BCG
at 1.2 × 107 CFU, according to the corresponding schedule (i.e.,
day 1 versus day 1 and day 6 versus day 6). All experiments were
performed in triplicate for reproducibility. F value of each treatment
group was determined by one-way ANOVA, and Dunnett’s posttest
was followed to determine P values.
are frequently mild cases, with the commonest cystitis, fever
and chills are at least partially linked with the induction
of endogenous inflammatory cytokines in the bladder [5].
The incubation of NF-κB, which is a transcriptional factor
for many cytokines, including the IL-6 induced by GLe on
HUC-PC cells [12], was shown to bear antitumor eﬀects in
other bladder cancer cells [34]. Interstitial cystitis is a form of
inflammatory hypersensitivity characterized with high levels
IL-6 and histamine in patients’ urine [35]. This imposes
another question whether the regulatory roles of GLe on
BCG-mediated IL-6 and IL-8 would reduce also the side
eﬀects of BCG? However, more in-depth investigations are
required using animal models.
Furthermore,MCP-1 expression of the HUC-PC cultures
were dose-dependently inhibited by the treatments of BCG
or GLe alone, combination therapy of BCG and GLe,
and GLe pretreatment followed by BCG. It has reported
that MCP-1 levels produced in the urine have directly
correlated with the bladder cancer stages and grades [36].
Contradictorily, MCP-1 was elevated in the serum and
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Figure 4: Dose-response curves of (a) BCG and (b) GLe generated by nonlinear regression, in order to define the sinGLe-agent eﬀects
as IC70. On day 6 following drug cessation, and since only selected BCG concentrations were tested, the BCG cytotoxicity showed ranged
from 60–73% when compared with the solvent control (i.e., BCG 0CFU on day 6). In order to minimize the error, IC70 was used for
isobologram analysis. Isobolograms (c) were plotted for treatments 3 and 4 with the IC70 determined for BCG and GLe. Concentrations of
GLe and BCG were reflected on x- and y-axes, respectively. Area below the additive isobole (the line joining IC70,BCG and IC70,GLe) indicates
synergistic interaction. Combination indices (CI) were calculated as CI = CBCG,70/IC70,BCG + CGLe,70/IC70,GLe according to Zhao et al. [14].
Specifically, CBCG,70 and CGLe,70 are the concentrations of BCG and GLe used in treatments 3 and 4 to achieve 70% drug eﬀect. IC70,BCG (fixed
as 1.2×107 CFU for all experiments) and IC70,GLe (19.12 μg/mL in treatment 3; 12.37 μg/mL in treatment 4) are the concentrations for sinGLe
agents to achieve the same eﬀect.
bladder biopsy of bladder cancer patients following BCG
immunotherapy [37]. The chemoattracting properties of
MCP-1 were believed to be involved for tumor eradication;
however, more recent studies have also demonstrated the
roles of MCP-1 in angiogenesis and promoting tumor
progression [11]. The pro- and antitumor eﬀects of MCP-
1 remain controversial, but facts presented in this study have
indicated that the premalignant HUC-PC cells were capable
forMCP-1 production, whereas in response toGLe, the levels
were significantly suppressed concurrently with the growth
inhibition. The degree of MCP-1 suppression was clearly
correlated with the cytotoxicity exerted by the combination
therapy and pretreatment schedule.
5. Conclusions
Novel findings have demonstrated the possible synergistic
interaction between BCG and GLe, in terms of adverse
TCC cells elimination. Both BCG and GLe were immuno-
logical active in the HUC-PC cells. However, the BCG-
provoked cytokines were inhibited when the cells were first
preincubated with GLe, proposing the potential implications
in reducing the inflammatory-related toxicity of BCG and
warranted more in-depth elucidation.
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